Overview

Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with liver or bile duct cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Brown University
Treatments:
Doxorubicin
Liposomal doxorubicin